CorMedix Inc. (CRMD) News
Track canonical SquawkNews coverage tagged to CRMD, CorMedix Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CorMedix Price Target Announced at $15.00/Share by Oppenheimer
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 10:42 AM UTC
L
CRMD cites diversified specialty pharma platform and new market opportunities
CRMD says it has evolved into a diversified specialty pharma with eight marketed products and a scalable institutional platform, citing reimbursement transition, Medicare Advantage focus, REZZAYO expansion potential, and
EQUITY | Sep 09, 2026, 06:06 PM UTC
L
CRMD: Diversified portfolio, robust cash, and new indications position the company for strong institutional growth
The company has transformed into a diversified specialty pharma with eight marketed products and a scalable institutional platform. DefenCath’s reimbursement transition and Medicare Advantage efforts are key near-term dr
EQUITY | Sep 09, 2026, 05:39 PM UTC
L
CRMD: Strong revenue growth, pipeline expansion, and financial flexibility drive continued value creation
A diversified specialty pharma business with a strong institutional focus, robust product portfolio, and scalable commercial platform is delivering sustained revenue growth and profitability. DefenCath and REZZAYO drive
EQUITY | Sep 09, 2026, 12:51 PM UTC
L
CorMedix Therapeutics to participate in Wells Fargo Healthcare Conference
CorMedix Therapeutics said senior management will participate in a fireside at the Wells Fargo Healthcare Conference.
EQUITY | Sep 01, 2026, 12:37 PM UTC
L
CRMD - CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
CRMD - CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
EQUITY | Sep 01, 2026, 12:31 PM UTC
L
CorMedix tops Q2 estimates, raises adjusted EBITDA guidance
CorMedix Inc. reported second-quarter adjusted EPS of 29 cents and revenue of $101.9 million, both above consensus, and raised adjusted EBITDA guidance while reaffirming fiscal 2026 sales guidance.
EARNINGS | Aug 13, 2026, 02:56 PM UTC
L
CorMedix surges after better-than-expected Q2 results
CorMedix Inc. (NASDAQ: CRMD) surged 23.6% after the company reported better-than-expected second-quarter financial results.
EARNINGS | Aug 13, 2026, 01:57 PM UTC
L
Cormedix Q2 revenue, EBITDA rise; guidance lifted
Cormedix reported second-quarter revenue of $101.9 million and adjusted EBITDA of $58.7 million, signed a multi-year DefenCath supply deal with another large dialysis organization, and raised full-year adjusted EBITDA gu
EARNINGS | Aug 13, 2026, 01:07 PM UTC
L
Cormedix affirms FY2026 sales guidance at $325M–$345M
Cormedix (NASDAQ: CRMD) affirms FY2026 sales guidance of $325.000M–$345.000M, compared with a $334.089M estimate, with the range unchanged from the prior outlook.
EARNINGS | Aug 13, 2026, 11:30 AM UTC
L
Cormedix Therapeutics reports Q2 2026 results and business update
Cormedix Therapeutics (CRMD) reports its second quarter 2026 financial results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 11:30 AM UTC
L
CRMD - CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 - Click For R
CRMD - CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
EARNINGS | Jul 29, 2026, 12:31 PM UTC
L
CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer
() -- CorMedix (CRMD) board has appointed chief operating officer, Elizabeth Hurlburt, to the newly created role of chief operating and commercial officer, the company said in a late Thursday filing. As part of this lead
EQUITY | Jul 02, 2026, 08:52 PM UTC
L
CorMedix shares are trading higher. The company announced its Audit Committee approved changing the independent public accounting firm, dism
CorMedix shares are trading higher. The company announced its Audit Committee approved changing the independent public accounting firm, dismissing CBIZ CPAs.
EQUITY | Jul 01, 2026, 05:16 PM UTC
H
Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Wednesday. Shares of Nike Inc (NYSE: NKE ) fell sharply in pre-market trading after the company reported fourth-quarter res
EARNINGS | Jul 01, 2026, 12:02 PM UTC